JP2016527286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527286A5 JP2016527286A5 JP2016532266A JP2016532266A JP2016527286A5 JP 2016527286 A5 JP2016527286 A5 JP 2016527286A5 JP 2016532266 A JP2016532266 A JP 2016532266A JP 2016532266 A JP2016532266 A JP 2016532266A JP 2016527286 A5 JP2016527286 A5 JP 2016527286A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- amino acid
- interleukin
- combined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019123809A JP7565678B2 (ja) | 2013-08-08 | 2019-07-02 | 組合せ医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003964.7 | 2013-08-08 | ||
| EP13003964 | 2013-08-08 | ||
| PCT/EP2014/002182 WO2015018529A1 (en) | 2013-08-08 | 2014-08-08 | Combined pharmaceutical composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019123809A Division JP7565678B2 (ja) | 2013-08-08 | 2019-07-02 | 組合せ医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527286A JP2016527286A (ja) | 2016-09-08 |
| JP2016527286A5 true JP2016527286A5 (OSRAM) | 2017-08-24 |
| JP6794255B2 JP6794255B2 (ja) | 2020-12-02 |
Family
ID=48951300
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532266A Active JP6794255B2 (ja) | 2013-08-08 | 2014-08-08 | 組合せ医薬組成物 |
| JP2019123809A Active JP7565678B2 (ja) | 2013-08-08 | 2019-07-02 | 組合せ医薬組成物 |
| JP2022063995A Pending JP2022091985A (ja) | 2013-08-08 | 2022-04-07 | 組合せ医薬組成物 |
| JP2024092095A Withdrawn JP2024116254A (ja) | 2013-08-08 | 2024-06-06 | 組合せ医薬組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019123809A Active JP7565678B2 (ja) | 2013-08-08 | 2019-07-02 | 組合せ医薬組成物 |
| JP2022063995A Pending JP2022091985A (ja) | 2013-08-08 | 2022-04-07 | 組合せ医薬組成物 |
| JP2024092095A Withdrawn JP2024116254A (ja) | 2013-08-08 | 2024-06-06 | 組合せ医薬組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20160184399A1 (OSRAM) |
| EP (2) | EP3030262B1 (OSRAM) |
| JP (4) | JP6794255B2 (OSRAM) |
| KR (3) | KR102457731B1 (OSRAM) |
| CN (1) | CN105579062A (OSRAM) |
| CA (1) | CA2920539C (OSRAM) |
| CY (1) | CY1122465T1 (OSRAM) |
| DK (1) | DK3030262T3 (OSRAM) |
| ES (1) | ES2760249T3 (OSRAM) |
| HR (1) | HRP20192174T1 (OSRAM) |
| HU (1) | HUE046964T2 (OSRAM) |
| LT (1) | LT3030262T (OSRAM) |
| PL (1) | PL3030262T3 (OSRAM) |
| PT (1) | PT3030262T (OSRAM) |
| RS (1) | RS59756B1 (OSRAM) |
| SI (1) | SI3030262T1 (OSRAM) |
| SM (1) | SMT201900684T1 (OSRAM) |
| WO (1) | WO2015018529A1 (OSRAM) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2529747T (pt) | 2005-12-02 | 2018-05-09 | Icahn School Med Mount Sinai | Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações |
| MD4655C1 (ro) | 2013-03-14 | 2020-06-30 | Icahn School Of Medicine At Mount Sinai | Virusurile bolii de Newcastle şi utilizarea acestora |
| EP3030262B1 (en) * | 2013-08-08 | 2019-10-09 | Cytune Pharma | Combined pharmaceutical composition |
| CN105263521B (zh) * | 2014-01-15 | 2021-06-29 | 卡德门企业有限公司 | 免疫调节剂 |
| US20170000832A1 (en) | 2014-02-27 | 2017-01-05 | Viralytics Limited | Combination method for treatment of cancer |
| EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| US11655452B2 (en) | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| EP3350205A1 (en) * | 2015-09-16 | 2018-07-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Specific interleukin-15 (il-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases |
| WO2017123643A1 (en) * | 2016-01-11 | 2017-07-20 | Flagship Pioneering, Inc. | Methods and compositions for modulating thymic function |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2017201352A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| CA3029813A1 (en) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| EP4353750A3 (en) * | 2016-06-24 | 2024-07-24 | iCell Gene Therapeutics LLC | Chimeric antigen receptors (cars), compositions and methods thereof |
| ES2972406T3 (es) * | 2016-08-01 | 2024-06-12 | Virogin Biotech Canada Ltd | Vectores del virus oncolítico del herpes simple que expresan moléculas estimuladoras del sistema inmunitario |
| CN110214148A (zh) * | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| SG11202000555UA (en) | 2017-06-21 | 2020-02-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| KR20210032924A (ko) | 2017-09-05 | 2021-03-25 | 토크 테라퓨틱스, 인코포레이티드 | 치료용 단백질 조성물 및 그의 제조 및 사용 방법 |
| AU2018388583A1 (en) * | 2017-12-19 | 2020-06-11 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
| KR20200128116A (ko) | 2018-02-28 | 2020-11-11 | 화이자 인코포레이티드 | Il-15 변이체 및 이의 용도 |
| EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| CA3097625A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| AU2019256539A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
| US12391957B2 (en) | 2018-08-17 | 2025-08-19 | Icahn School Of Medicine At Mount Sinai | Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease |
| CR20210239A (es) | 2018-10-12 | 2021-12-15 | Xencor Inc | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas |
| US11618776B2 (en) | 2018-12-20 | 2023-04-04 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains |
| KR20220012296A (ko) * | 2019-05-20 | 2022-02-03 | 싸이튠 파마 | 암 또는 감염성 질환 치료를 위한 IL-2/IL-15Rβγ 작용제 투여 요법 |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| CN114787181A (zh) * | 2019-11-21 | 2022-07-22 | Inserm(法国国家健康医学研究院) | 用抗pd-1/il-15免疫细胞因子靶向pd-1的新型免疫疗法 |
| KR20230096047A (ko) * | 2020-10-26 | 2023-06-29 | 싸이튠 파마 | 비흑색종 피부암 치료용 IL-2/IL-15Rβγ 작용제 |
| US20240199750A1 (en) | 2021-03-26 | 2024-06-20 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| KR20240019297A (ko) | 2021-06-09 | 2024-02-14 | 이나뜨 파르마 에스.에이. | Nkp46, 사이토카인 수용체, 종양 항원 및 cd16a 에 결합하는 다중특이적 단백질 |
| EP4362957A1 (en) | 2021-07-01 | 2024-05-08 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| CA3259982A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics Inc | COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| AU2024231622A1 (en) * | 2023-03-07 | 2025-08-28 | Hanmi Pharm. Co., Ltd. | Combination therapy of Interleukin-2 (IL-2) analog or conjugate thereof and immune checkpoint inhibitor for preventing or treating cancer |
| CN120857938A (zh) * | 2023-03-07 | 2025-10-28 | 韩美药品株式会社 | 用于预防或治疗癌症的包括白细胞介素-2(il-2)类似物或其缀合物的药物组合物 |
| US20250243279A1 (en) | 2023-10-17 | 2025-07-31 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5997856A (en) | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5108910A (en) | 1989-08-22 | 1992-04-28 | Immunex Corporation | DNA sequences encoding fusion proteins comprising GM-CSF and IL-3 |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| WO2000037504A2 (en) | 1998-12-23 | 2000-06-29 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7740845B2 (en) | 2000-10-18 | 2010-06-22 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| WO2004035607A2 (en) | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| EP1718670B1 (en) | 2004-02-27 | 2011-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity |
| DK2287195T3 (da) | 2004-07-01 | 2019-08-19 | Innate Pharma | Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi |
| WO2006056875A1 (en) | 2004-11-29 | 2006-06-01 | Pharmacia & Upjohn Company Llc | Thiazepine oxazolidinones as antibacterial agents |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| PL1899364T5 (pl) | 2005-05-17 | 2024-12-09 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| CA2669921A1 (en) | 2006-11-15 | 2008-06-26 | Medarex, Inc. | Human monoclonal antibodies to btla and methods of use |
| NZ720288A (en) | 2006-12-27 | 2020-02-28 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| JP2010523478A (ja) | 2007-03-22 | 2010-07-15 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | モノクローナル抗体８ｈ９の使用 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| AU2008269032B2 (en) * | 2007-06-27 | 2013-12-05 | Novartis Ag | Complexes of IL-15 and IL-15Ralpha and uses thereof |
| TW200938224A (en) | 2007-11-30 | 2009-09-16 | Medarex Inc | Anti-B7H4 monoclonal antibody-drug conjugate and methods of use |
| PL2242773T3 (pl) | 2008-02-11 | 2017-11-30 | Cure Tech Ltd. | Przeciwciała monoklonalne do leczenia nowotworu |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| WO2009135031A1 (en) | 2008-04-30 | 2009-11-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Substituted il-15 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP2927240A1 (en) | 2008-08-25 | 2015-10-07 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| EP2342229A1 (en) | 2008-09-12 | 2011-07-13 | ISIS Innovation Limited | Pd-1 specific antibodies and uses thereof |
| EP2342228B1 (en) | 2008-09-12 | 2017-09-06 | Oxford University Innovation Limited | Pd-1 specific antibodies and uses thereof |
| ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
| WO2010077634A1 (en) * | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US8741295B2 (en) | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
| EP3002296B1 (en) | 2009-03-17 | 2020-04-29 | Université d'Aix-Marseille | Btla antibodies and uses thereof |
| EP2459594A1 (en) | 2009-07-31 | 2012-06-06 | N.V. Organon | Fully human antibodies to btla |
| US9150656B2 (en) | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| CN105017429B (zh) * | 2010-09-21 | 2021-04-06 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| US9220776B2 (en) | 2011-03-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| PL2699264T3 (pl) | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1 |
| EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| ES2747997T3 (es) * | 2012-10-24 | 2020-03-12 | Novartis Ag | Formas de IL-15R alfa, células que expresan formas de IL-15R alfa, y usos terapéuticos de IL-15R alfa y complejos IL-15/IL-15R alfa |
| EP3030262B1 (en) | 2013-08-08 | 2019-10-09 | Cytune Pharma | Combined pharmaceutical composition |
-
2014
- 2014-08-08 EP EP14761281.6A patent/EP3030262B1/en active Active
- 2014-08-08 JP JP2016532266A patent/JP6794255B2/ja active Active
- 2014-08-08 SI SI201431420T patent/SI3030262T1/sl unknown
- 2014-08-08 KR KR1020167005437A patent/KR102457731B1/ko active Active
- 2014-08-08 DK DK14761281T patent/DK3030262T3/da active
- 2014-08-08 CA CA2920539A patent/CA2920539C/en active Active
- 2014-08-08 SM SM20190684T patent/SMT201900684T1/it unknown
- 2014-08-08 HR HRP20192174TT patent/HRP20192174T1/hr unknown
- 2014-08-08 KR KR1020227036248A patent/KR20220148304A/ko not_active Ceased
- 2014-08-08 PL PL14761281T patent/PL3030262T3/pl unknown
- 2014-08-08 CN CN201480052637.3A patent/CN105579062A/zh active Pending
- 2014-08-08 HU HUE14761281A patent/HUE046964T2/hu unknown
- 2014-08-08 PT PT147612816T patent/PT3030262T/pt unknown
- 2014-08-08 EP EP19201668.1A patent/EP3659622A1/en active Pending
- 2014-08-08 US US14/910,491 patent/US20160184399A1/en not_active Abandoned
- 2014-08-08 LT LTEP14761281.6T patent/LT3030262T/lt unknown
- 2014-08-08 ES ES14761281T patent/ES2760249T3/es active Active
- 2014-08-08 RS RS20191542A patent/RS59756B1/sr unknown
- 2014-08-08 KR KR1020247021359A patent/KR102861895B1/ko active Active
- 2014-08-08 WO PCT/EP2014/002182 patent/WO2015018529A1/en not_active Ceased
-
2019
- 2019-07-02 JP JP2019123809A patent/JP7565678B2/ja active Active
- 2019-11-26 CY CY20191101235T patent/CY1122465T1/el unknown
-
2022
- 2022-02-22 US US17/677,589 patent/US20220168395A1/en active Pending
- 2022-03-15 US US17/695,688 patent/US20220202904A1/en active Pending
- 2022-04-07 JP JP2022063995A patent/JP2022091985A/ja active Pending
-
2024
- 2024-06-06 JP JP2024092095A patent/JP2024116254A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527286A5 (OSRAM) | ||
| JP7617839B2 (ja) | 融合構築物およびその使用法 | |
| ES3006183T3 (en) | Antibody molecules that bind pd-l1 and cd137 | |
| JP7397055B2 (ja) | Ｃｄ１３７及びｏｘ４０に結合する抗体分子 | |
| HRP20192174T1 (hr) | Kombinirani farmaceutski pripravak | |
| JP7474235B2 (ja) | ＯＸ４０抗原結合部位を含むＦｃ結合断片 | |
| JP2018501197A5 (OSRAM) | ||
| JP2016537340A5 (OSRAM) | ||
| JP2016539096A5 (OSRAM) | ||
| JP2016532693A5 (OSRAM) | ||
| WO2015037000A1 (en) | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases | |
| WO2014089169A4 (en) | Immunotherapy with binding agents | |
| RU2016122957A (ru) | Способы применения интерлейкина-10 для лечения заболеваний и расстройств | |
| FI3421486T3 (fi) | Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi | |
| JP2017534633A5 (OSRAM) | ||
| JP2023165946A (ja) | Ｅｐ４阻害剤およびその使用 | |
| JP2020521478A5 (OSRAM) | ||
| AU2021202634B2 (en) | Hla-b57 open conformers | |
| JP2019526528A5 (OSRAM) | ||
| JP2020517658A5 (OSRAM) | ||
| ES3040993T3 (en) | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy | |
| CN113543809A (zh) | 用于治疗癌症的免疫疗法 | |
| JP2019517508A5 (OSRAM) | ||
| CN114599398A (zh) | 用gm-csf拮抗剂治疗癌症 | |
| JP7644151B2 (ja) | 抗ｐｄ－１抗体および融合タンパク質 |